ETBX-061 clinical trials

Studies by the year they started

18 studies that test it; most in 2018 (11)

Who runs them

Industry 17 · Other 1

ImmunityBio, Inc. (17) · National Cancer Institute (NCI) (1)

Often tested with

Tested in the same studies.

Nogapendekin alfa inbakicept (17) · Avelumab (17) · ETBX-051 (16) · GI-6301 (16) · Cyclophosphamide (16) · Fluorouracil (16) · Leucovorin (15) · Paclitaxel (15)

Studies

Open first, then newest update. How each study uses ETBX-061 is read from its arms, and is right about nine times in ten.

Testing it · 18

• QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as ETBX-061
• QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169790Written as ETBX-061
• QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as ETBX-061
• QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as ETBX-061
• QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as ETBX-061
• QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnPhase 1/2ImmunityBio, Inc.NCT03647423Written as ETBX-061
• QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167164Written as ETBX-061
• QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197584Written as ETBX-061
• QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as ETBX-061
• QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as ETBX-061
• QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as ETBX-061
• QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as ETBX-061
• QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as ETBX-061
• QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as ETBX-061
• QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as ETBX-061
• QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as ETBX-061
• Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy VaccinesCompletedPhase 1National Cancer Institute (NCI)NCT03481816Written as ETBX-061; adenoviral MUC1 vaccine
• QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/2ImmunityBio, Inc.NCT03563170Written as ETBX-061

Codes

What other systems call ETBX-061 · ClinicalTrials.gg INT014290

• UNII (FDA) 17K7SN702NETBX-061One source FDA
• NCI Thesaurus C143035Adenoviral MUC1 Vaccine ETBX-061One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.